Surveillance Methods & Vaccine Safety
To detect the ‘needle in the haystack’ of a rare adverse event, pharmacovigilance employs massive epidemiological surveillance techniques. This unit explores the core differences between waiting for doctors to report ADRs (Passive Surveillance) versus actively hunting for them (Active Surveillance, Registries). Furthermore, it dedicates an entire section to the hyper-sensitive field of Vaccine Pharmacovigilance (AEFI) and the vital art of Crisis Communication when a drug disaster strikes.
Syllabus & Topics
- 1Vaccine Safety Surveillance: Why it’s different: Vaccines are given to millions of perfectly healthy infants for disease prevention. Therefore, public tolerance for any adverse effect is virtually zero. Adverse Events Following Immunization (AEFI): Any untoward medical occurrence following immunization (not necessarily caused by the vaccine). Categories: Vaccine product-related (e.g., actual allergy to egg protein in the vial), Vaccine quality defect (e.g., contaminated vial), Immunization error-related (e.g., nurse uses the wrong diluent), Immunization anxiety-related (fainting from needle fear), Coincidental event (e.g., infant coincidentally caught a cold the same day). Vaccination Failure: When the immunological response fails to protect against the targeted disease.
- 2Pharmacovigilance Methods: Passive Surveillance: The backbone of global PV. Relying on healthcare professionals to voluntarily submit Spontaneous Reports (e.g., Yellow Cards) when they suspect an ADR in their daily practice. Pros: Cheap, covers all drugs continuously. Cons: Massive under-reporting, poor data quality, impossible to calculate the true ‘incidence rate’ (you don’t know the denominator of total patients taking the drug).
- 3Pharmacovigilance Methods: Active Surveillance & Stimulated Reporting: Stimulated reporting occurs when the FDA publicly urges doctors to report issues for a newly launched drug. Active Surveillance: Systematically and continuously collecting data on ALL patients taking a specific drug, regardless of whether they have an ADR. Sentinel Sites: Carefully selected hospitals strictly monitored to evaluate a specific safety concern. Drug Event Monitoring (Prescription Event Monitoring – PEM): Following up with doctors who prescribed a new drug to aggressively ask about adverse events.
- 4Registries & Comparative Observational Studies: Disease or Pregnancy Registries: Long-term databases tracking every patient with a specific disease or pregnant women on a specific drug to massively analyze outcomes. Observational Studies: Cross-sectional: A ‘snapshot’ in time measuring both exposure and disease simultaneously. Case-control: Retrospective study—taking sick patients (cases) and healthy people (controls) and looking backward in time to see if the sick people took the drug more often. Cohort study: Prospective—taking healthy people, giving half the drug, and watching them over years to see who gets sick.
- 5Targeted Clinical Investigations: Phase 4 studies specifically requested by regulatory bodies (like the FDA) after a drug is already on the market, solely designed to confirm or refute a highly specific safety signal detected via spontaneous reporting.
- 6Communication in Pharmacovigilance: The Crisis: When an ADR causes a global panic, the ensuing media frenzy can destroy public trust in essential medicines. Effective Communication: Must be rapid, transparent, and scientifically factual without causing unnecessary alarm. Targets: Communicating urgently with Regulatory Agencies (to update labels/withdraw the drug), Healthcare Facilities (sending ‘Dear Healthcare Professional’ letters advising doctors to stop prescribing), and managing the Media narrative objectively.
Learning Objectives
Exam Prep Questions
Q1. Why is “Under-reporting” the biggest flaw of Passive Spontaneous Reporting?
Passive spontaneous reporting depends entirely on healthcare professionals voluntarily reporting adverse drug reactions. In reality, busy clinicians often do not have enough time to complete detailed ADR reporting forms.
Additionally, if the reaction appears mild or if the doctor is unsure whether the drug truly caused the reaction, the event may not be reported. Studies estimate that up to 90–95% of ADRs go unreported worldwide. As a result, pharmacovigilance databases capture only a small portion of actual drug-related problems, often described as just the “tip of the iceberg.”
Q2. If a baby develops fever after a DPT vaccine, why is it called an AEFI instead of an ADR?
In vaccine safety monitoring, the correct initial term is AEFI (Adverse Event Following Immunization). This term simply records that a medical event occurred after vaccination, without assuming that the vaccine caused it.
The term ADR (Adverse Drug Reaction) is only used after a formal investigation confirms a causal relationship between the drug or vaccine and the reaction. For example, if a baby develops fever a few hours after a vaccine, the fever could be related to the vaccine—or it could be due to an unrelated infection. Therefore, the event is first recorded as an AEFI until causality is evaluated.
Q3. Why use a retrospective Case-Control study instead of a prospective Cohort study?
A Case-Control study is particularly useful when studying rare diseases or adverse effects. In such cases, conducting a prospective cohort study would require following millions of individuals for many years just to observe a small number of cases.
In a case-control study, researchers begin with people who already have the disease (cases) and compare them with similar people without the disease (controls). They then look backward in time to determine whether exposure to a suspected drug or risk factor was more common among the cases. This method is much faster, cheaper, and practical for investigating rare outcomes.